Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C

Journal of Gastroenterology

Volumn 46, Issue 6, 2011, Pages 790-798

  Takahashi, Hirokazu ^a   Mizuta, Toshihiko ^a   Eguchi, Yuichiro ^a   Kawaguchi, Yasunori ^a   Kuwashiro, Takuya ^a   Oeda, Satoshi ^a   Isoda, Hiroshi ^a   Oza, Noriko ^a   Iwane, Shinji ^a   Izumi, Kenichi ^a   Anzai, Keizou ^a   Ozaki, Iwata ^a   Fujimoto, Kazuma ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

Hepatitis C; Hepatocellular carcinoma; Hyperglycemia; Oral glucose tolerance test

Indexed keywords

GLUCOSE; INSULIN; INTERFERON;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CANCER RISK; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; VIRUS LOAD;

ADULT; AGE FACTORS; AGED; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; HEPATITIS C, CHRONIC; HUMANS; HYPERGLYCEMIA; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS;

EID: 79960268165     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-011-0381-2     Document Type: Article

References (39)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52. (Pubitemid 32634271)
2. Poynard T, Bedossa P, Oplon P, for the OBSTIRC, METAVIR, CLINIVIR and DOSVIRC groups. Nature history of liver fibrous progression in patients with chronic hepatitis C. Lancet. 1997;349:825-32. (Pubitemid 27129209)
3. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340:1228-33. (Pubitemid 29181642)
4. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998;28:805-9. (Pubitemid 28405433)
5. Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology. 2004;126: 1024-9.
6. Hung CH, Chen CH, Lee CM, Wu CM, Hu TH, Wang JH, et al. Association of amino acid variations in the NS5A and E2-PePHD region of hepatitis C virus 1b with hepatocellular carcinoma. J Viral Hepat. 2008;15:58-65.
7. Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology. 2008;47:1856-62. (Pubitemid 351945553)
8. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135:111-21.
9. Tung HD, Wang JH, Tseng PL, Hung CH, Kee KM, Chen CH, et al. Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies. Am J Gastroenterol. 2010;105:624-31.
10. Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology. 2006;43:1295-302. (Pubitemid 43980108)
11. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med. 1999;131:174-81.
12. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma, decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 1997;27:201-5. (Pubitemid 27357077)
13. Tarao K, Rino Y, Ohkawa S, Shimizu A, Tamai S, Miyakawa K, et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus associated cirrhosis. Cancer. 1999;86:589-95. (Pubitemid 29379404)
14. Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer. 2007;109: 2490-946.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9. (Pubitemid 15018832)
16. Ikeda Y, Suehiro T, Nakamura T, Kumon Y, Hashimoto K. Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. Endocr J. 2001;48:81-6. (Pubitemid 32230388)
17. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293. (Pubitemid 26260021)
18. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681-7.
19. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615-25. (Pubitemid 40770750)
20. Tanaka H, Fujita N, Sugimoto R, Urawa N, Horiike S, Kobayashi Y, et al. Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C. Br J Cancer. 2008;98:580-6. (Pubitemid 351214532)
21. Jüngst C, Cheng B, Gehrke R, Schmitz V, Nischalke HD, Ramakers J, et al. Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma. Hepatology. 2004; 39:1663-72. (Pubitemid 38702668)
22. Oka R, Hifumi S, Kobayashi J, Mabuchi H, Asano A, Yagi K, et al. The relationship between post-prandial plasma glucose and post-challenge plasma glucose in Japanese population. Diabetes Res Clin Pract. 2007;78:282-8. (Pubitemid 47451538)
23. Ito C, Maeda R, Ishida S, Sasaki H, Harada H. Correlation among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c. Diabetes Res Clin Pract. 2000;50:225-30.
24. Tsugane S, Inoue M. Insulin resistance and cancer: epidemiological evidence. Cancer Sci. 2010;101:1073-9.
25. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4:369-80. (Pubitemid 43343895)
26. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126:840-8. (Pubitemid 38298332)
27. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol. 2004;165:1499-508. (Pubitemid 39435150)
28. Persico M, Masarone M, La Mura V, Persico E, Moschella F, Svelto M, et al. Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities. World J Gastroenterol. 2009;15:462-6.
29. Eguchi Y, Mizuta T, Ishibashi E, Kitajima Y, Oza N, Nakashita S, et al. Hepatitis C virus infection enhances insulin resistance induced by visceral fat accumulation. Liver Int. 2009;29:213-20.
30. Konishi I, Hiasa Y, Shigematsu S, Hirooka M, Furukawa S, Abe M, et al. Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus. Liver Int. 2009;29:1194-201.
31. Cacciatore L, Cozzolino G, Giardina MG, De Marco F, Sacca L, Esposito P, et al. Abnormalities of glucose metabolism induced by liver cirrhosis and glycosylated hemoglobin levels in chronic liver disease. Diabetes Res. 1988;7:185-8.
32. Bando Y, Kanehara H, Toya D, Tanaka N, Kasayama S, Koga M. Association of serum glycated albumin to haemoglobin A1C ratio with hepatic function tests in patients with chronic liver disease. Ann Clin Biochem. 2009;46:368-72.
33. Qiao Q, Lindström J, Valle TT, Tuomilehto J. Progression to clinically diagnosed and treated diabetes from impaired glucose tolerance and impaired fasting glycaemia. Diabet Med. 2003; 20:1027-33. (Pubitemid 41701485)
34. Nakagami T, Tajima N, Oizumi T, Karasawa S, Wada K, Kameda W, et al. Hemoglobin A1c in predicting progression to diabetes. Diabetes Res Clin Pract. 2010;87:126-31.
35. DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care. 2003;26:688-96.
36. Nakagami T, DECODA Study Group. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia. 2004;47:385-94. (Pubitemid 38491233)
37. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346:1051-5.
38. Kasai D, Adachi T, Deng L, Nagano-Fujii M, Sada K, Ikeda M, et al. HCV replication suppresses cellular glucose uptake through down-regulation of cell surface expression of glucose transporters. J Hepatol. 2009;50:883-94.
39. Kawaguchi Y, Mizuta T, Oza N, Takahashi H, Ario K, Akiyama T, et al. Eradication of hepatitis C virus by interferon improves whole-body insulin resistance and hyperinsulinaemia in patients with chronic hepatitis C. Liver Int. 2009;29:871-7.